Palisade Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2011-09-06
- Employees
- 9
- Market Cap
- -
- Website
- http://www.palisadebio.com
- Introduction
Palisades Goldcorp Ltd is a Canadian resource merchant bank. The company is engaged in investing in resource properties.
Clinical Trials
3
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1 Study Evaluating PALI-2108 in Healthy Volunteers and Ulcerative Colitis Patients.
- Conditions
- Ulcerative Colitis (UC)Healthy Volunteer
- Interventions
- Drug: PALI-2108 Placebo
- First Posted Date
- 2024-10-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Palisade Bio
- Target Recruit Count
- 90
- Registration Number
- NCT06663605
- Locations
- 🇨🇦
Altasciences, Montreal, Quebec, Canada
A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Palisade Bio
- Target Recruit Count
- 23
- Registration Number
- NCT05470387
- Locations
- 🇺🇸
Site 315, Mobile, Alabama, United States
🇺🇸Site 354, La Jolla, California, United States
🇺🇸Site 329, Orange, California, United States
A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Palisade Bio
- Target Recruit Count
- 112
- Registration Number
- NCT02836470
- Locations
- 🇺🇸
Site 315, Mobile, Alabama, United States
🇺🇸Site 307, Yuma, Arizona, United States
🇺🇸Site 329, Irvine, California, United States
News
Palisade Bio Advances PALI-2108 for Ulcerative Colitis Treatment into Multiple Ascending Dose Study
Palisade Bio has initiated the multiple ascending dose (MAD) cohorts of its Phase Ia/b trial for PALI-2108 in ulcerative colitis after completing single ascending dose (SAD) cohorts.
Palisade Bio's PALI-2108 Shows Promise in Ulcerative Colitis Preclinical Studies
PALI-2108, a colon-specific PDE4 inhibitor prodrug, effectively reduced colitis symptoms in a DSS mouse model, suggesting potential for ulcerative colitis (UC) treatment.
Alto Neuroscience's ALTO-100 Fails Phase 2b Trial for Major Depressive Disorder
Alto Neuroscience's ALTO-100 failed to meet its primary endpoint in a Phase 2b trial for major depressive disorder (MDD), as measured by the MADRS scale.
Palisade Bio Advances PALI-2108 for Ulcerative Colitis with Phase 1 Trial Imminent
Palisade Bio is set to initiate a Phase 1 clinical trial for PALI-2108, a PDE4 inhibitor prodrug, targeting moderate to severely active ulcerative colitis (UC).
Palisade Bio Identifies PDE4B as Potential Biomarker for Ulcerative Colitis Patient Stratification
Palisade Bio identifies PDE4B expression as a potential biomarker for patient stratification in ulcerative colitis (UC), with higher expression in colitis patients.